Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Gene therapy’s duration is less than Krystal clear
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Krystal plays down dropout to claim a mid-stage win
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.
Fibrocell gets a reality check
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.
Gene therapies go skin deep to tackle epidermolysis bullosa
Three gene therapy contenders, Abeona, Fibrocell and Krystal, are taking different approaches in the quest to cure epidermolysis bullosa.
Krystal gets more skin in the epidermolysis bullosa game
Krystal Biotech shares surged after positive data with its epidermolysis bullosa project, KB103, in just two patients. Now it needs to repeat the trick.
Krystal gets a flying start in epidermolysis bullosa gene therapy
Krystal Biotech shares have surged 53% so far this week on gene therapy data in two patients, but rivals are waiting in the wings.
Upcoming events – Uniqure and Krystal await gene therapy readouts
Early data are due for Krystal Biotech’s epidermolysis bullosa project and Uniqure’s haemophilia B candidate.
